Literature DB >> 22231383

Endothelial function in children and adolescents with mucopolysaccharidosis.

Aaron S Kelly1, Andrea M Metzig, Julia Steinberger, Elizabeth A Braunlin.   

Abstract

BACKGROUND: Although coronary artery pathology is a prominent feature of mucopolysaccharidosis (MPS), it may be underestimated by coronary angiography because of its diffuse nature. It is also generally assumed that cardiovascular risk is increased in MPS and reduced following hematopoietic stem cell transplantation (HSCT) or enzyme replacement therapy (ERT), but this has never been formally evaluated. Non-invasive methods of assessing vascular endothelial function may provide a measure of cardiovascular risk in MPS. We evaluated endothelial function, using digital reactive hyperemia, in youth with MPS and in healthy controls.
METHODS: Digital reactive hyperemic index (RHI) was measured in 12 children and adolescents (age 10.3 ± 3.9 years old; 11 boys) with treated MPS and nine age- and gender-matched (11.4 ± 4.0; 8 boys) healthy controls. An independent t-test was used to compare RHI between individuals with MPS and controls.
RESULTS: Children and adolescents with MPS (MPS type II: N = 5; type I: N = 4; type VI: N = 3) whether treated by HSCT (N = 4) or ERT (N = 8) had significantly lower RHI compared to controls (MPS 1.22 ± 0.19 vs. controls 1.46 ± 0.32, p < 0.05).
CONCLUSION: These preliminary findings suggest that children and adolescents with treated MPS have significantly poorer endothelial function when compared to healthy controls. Further investigation into the utility of endothelial function for risk stratification and the long term implications of reduced endothelial function in MPS is warranted.

Entities:  

Mesh:

Year:  2012        PMID: 22231383      PMCID: PMC3684413          DOI: 10.1007/s10545-011-9438-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  23 in total

Review 1.  Cardiac allograft vasculopathy: advances in diagnosis.

Authors:  Qiangjun Cai; Umamahesh C Rangasetty; Alejandro Barbagelata; Kenichi Fujise; Michael M Koerner
Journal:  Cardiol Rev       Date:  2011 Jan-Feb       Impact factor: 2.644

2.  Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents.

Authors:  Elif Seda Selamet Tierney; Jane W Newburger; Kimberlee Gauvreau; Judith Geva; Elizabeth Coogan; Steven D Colan; Sarah D de Ferranti
Journal:  J Pediatr       Date:  2009-02-12       Impact factor: 4.406

3.  Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events.

Authors:  Ronen Rubinshtein; Jeffrey T Kuvin; Morgan Soffler; Ryan J Lennon; Shahar Lavi; Rebecca E Nelson; Geralyn M Pumper; Lilach O Lerman; Amir Lerman
Journal:  Eur Heart J       Date:  2010-02-24       Impact factor: 29.983

4.  Orthopedic management of mucopolysaccharide disease.

Authors:  Klane K White; Paul Harmatz
Journal:  J Pediatr Rehabil Med       Date:  2010

5.  Rheumatic mitral valve stenosis is associated with impaired flow-mediated dilatation.

Authors:  Abdullah Tekin; Göknur Tekin; Alpay Turan Sezgin; Cem Hücran; Osman Kizilkiliç; Tansel Erol; Haldun Müderrisoğlu
Journal:  Int J Cardiol       Date:  2007-04-03       Impact factor: 4.164

6.  Prognostic value of carotid intima-media thickness in detection of coronary atherosclerosis in patients with calcified aortic valve stenosis.

Authors:  Anna Kablak-Ziembicka; Tadeusz Przewlocki; Wieslawa Tracz; Piotr Podolec; Ireneusz Stopa; Magdalena Kostkiewicz; Jerzy Sadowski; Aleksandra Mura; Grzegorz Kopeć
Journal:  J Ultrasound Med       Date:  2005-04       Impact factor: 2.153

7.  Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia.

Authors:  Piero O Bonetti; Geralyn M Pumper; Stuart T Higano; David R Holmes; Jeffrey T Kuvin; Amir Lerman
Journal:  J Am Coll Cardiol       Date:  2004-12-07       Impact factor: 24.094

8.  Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study.

Authors:  Naomi M Hamburg; Michelle J Keyes; Martin G Larson; Ramachandran S Vasan; Renate Schnabel; Moira M Pryde; Gary F Mitchell; Jacob Sheffy; Joseph A Vita; Emelia J Benjamin
Journal:  Circulation       Date:  2008-05-05       Impact factor: 29.690

9.  The mild form of mucopolysaccharidosis type I (Scheie syndrome) is associated with increased ascending aortic stiffness.

Authors:  Attila Nemes; Remco G M Timmermans; J H Paul Wilson; Osama I I Soliman; Boudewijn J Krenning; Folkert J ten Cate; Marcel L Geleijnse
Journal:  Heart Vessels       Date:  2008-04-04       Impact factor: 2.037

10.  Aortic valve sclerosis is associated with systemic endothelial dysfunction.

Authors:  Elisa Poggianti; Lucia Venneri; Vlad Chubuchny; Zoltan Jambrik; Liz Andrea Baroncini; Eugenio Picano
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

View more
  10 in total

1.  Younger age is associated with lower reactive hyperemic index but not lower flow-mediated dilation among children and adolescents.

Authors:  Aaron S Kelly; Kara L Marlatt; Julia Steinberger; Donald R Dengel
Journal:  Atherosclerosis       Date:  2014-04-01       Impact factor: 5.162

2.  Considering Fabry, but Diagnosing MPS I: Difficulties in the Diagnostic Process.

Authors:  E J Langereis; I E T van den Berg; D J J Halley; B J H M Poorthuis; F M Vaz; J H J Wokke; G E Linthorst
Journal:  JIMD Rep       Date:  2012-10-30

3.  Perioperative medullary complications in spinal and extra-spinal surgery in mucopolysaccharidosis: a case series of three patients.

Authors:  N Pauchard; C Garin; J L Jouve; P Lascombes; P Journeau
Journal:  JIMD Rep       Date:  2014-07-20

4.  Arsenic exposure from drinking water and endothelial dysfunction in Bangladeshi adolescents.

Authors:  Shohreh F Farzan; Hem Mahbubul Eunus; Syed Emdadul Haque; Golam Sarwar; Akm Rabiul Hasan; Fen Wu; Tariqul Islam; Alauddin Ahmed; Mohammad Shahriar; Farzana Jasmine; Muhammad G Kibriya; Faruque Parvez; Margaret R Karagas; Yu Chen; Habibul Ahsan
Journal:  Environ Res       Date:  2022-01-08       Impact factor: 6.498

5.  Carotid intima-media thickness is increased in patients with treated mucopolysaccharidosis types I and II, and correlates with arterial stiffness.

Authors:  Raymond Y Wang; Elizabeth A Braunlin; Kyle D Rudser; Donald R Dengel; Andrea M Metzig; Kelly K Covault; Lynda E Polgreen; Elsa Shapiro; Julia Steinberger; Aaron S Kelly
Journal:  Mol Genet Metab       Date:  2013-11-12       Impact factor: 4.797

6.  Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I.

Authors:  Omar Khalid; Moin U Vera; Philip L Gordts; N Matthew Ellinwood; Philip H Schwartz; Patricia I Dickson; Jeffrey D Esko; Raymond Y Wang
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

7.  Vascular function in asthmatic children and adolescents.

Authors:  Leonardo Silva Augusto; Grazielle Caroline Silva; José Felippe Pinho; Rosária Dias Aires; Virgínia Soares Lemos; Lidiana Fátima Correa Ramalho; Nulma Souto Jentzsch; Maria Glória Rodrigues-Machado
Journal:  Respir Res       Date:  2017-01-17

8.  Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders.

Authors:  Christian J Hendriksz; Paul Harmatz; Roberto Giugliani; Jane Roberts; G Suren Arul
Journal:  Mol Genet Metab Rep       Date:  2018-03-07

9.  Glycosaminoglycan metabolism defects and atherosclerosis: frequent association of endothelial dysfunction in patients with Mucopolysaccharidosis.

Authors:  Shoji Yano; Kathryn Moseley; Lawrence Wong; Claudia Castelnovi; Colleen Azen; Zdena Pavlova
Journal:  J Inherit Metab Dis       Date:  2013-07-27       Impact factor: 4.982

10.  Human pulmonary artery endothelial cells in the model of mucopolysaccharidosis VI present a prohypertensive phenotype.

Authors:  Adam Golda; Agnieszka Jurecka; Karolina Gajda; Anna Tylki-Szymańska; Anna Lalik
Journal:  Mol Genet Metab Rep       Date:  2015-02-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.